Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development

Building on our previous work on ibrutinib-based reversible covalent Bruton’s tyrosine kinase (BTK) PROTACs, we explored a different irreversible BTK inhibitor poseltinib as the BTK binder for PROTAC development. Different from ibrutinib, converting the irreversible cysteine reacting acrylamide grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xin, Guo, Wen-Hao, Lin, Hanfeng, Cheng, Ran, Monroy, Erika Y., Jin, Feng, Ding, Lang, Lu, Dong, Qi, Xiaoli, Wang, Meng C., Wang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879287/
https://www.ncbi.nlm.nih.gov/pubmed/36712232
http://dx.doi.org/10.1016/j.crchbi.2022.100029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879287/
https://www.ncbi.nlm.nih.gov/pubmed/36712232
http://dx.doi.org/10.1016/j.crchbi.2022.100029

Ejemplares similares